IDEXX Laboratories acquires CoVetAI: what it means for IDEXX Laboratories stock
Published on 10/07/2026 at 02:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories (US45168D1046) acquired CoVetAI on September 16, 2026, adding AI-native workflow software to its veterinary diagnostics and practice-management ecosystem. According to IDEXX Laboratories, financial terms were not disclosed, leaving integration and customer adoption as the main execution variables.
CoVetAI expands software reach
CoVetAI provides ambient-listening and clinical-workflow software that captures information from consultation through treatment planning and client follow-up. The company said more than 10,000 clinics globally use IDEXX cloud-based practice-management systems, giving the acquisition a large installed software base for potential distribution.
The transaction also preserves compatibility with third-party ambient scribe tools and non-IDEXX practice-management systems. That structure makes the deal an ecosystem expansion rather than a closed software migration, while the release identified software integration and customer acceptance as specific risks.
Second-quarter revenue grew 9.70 percent
MarketBeat reported that IDEXX generated USD 1.22 billion of revenue in the second quarter of 2026, up 9.70 percent from the same quarter of 2025. Diluted earnings per share were USD 4.27, above the USD 3.94 consensus, while the prior-year figure was USD 3.50.
The same report placed fiscal 2026 earnings per share guidance at USD 14.69-14.94. The comparison matters because the acquisition is being added to a business that was already expanding revenue and earnings before any disclosed contribution from CoVetAI.
What CoVetAI means for IDEXX
The strategic case is the connection between workflow data and diagnostic utilization. IDEXX said the combined tools could surface patient insights at clinical decision points, support more personalized client communication, and create capacity for veterinary teams to see more patients.
On Nasdaq, IDEXX was last at USD 515.41 on October 6, 2026 at 4:00 p.m. ET. Its market capitalization was USD 40.7 billion, and the USD 500.61 to USD 769.98 52-week range places the quote USD 254.57 below the high, a 33.06 percent gap.
Euro reference remains the prior close
The prior close at Lang & Schwarz was EUR 457.75 on October 5, 2026. The primary Nasdaq quotation and the euro reference use different venues and currencies, so the two values are kept separate.
The further course of trading is shown by the continuously updated real-time quote of IDEXX Laboratories stock.
IDEXX Laboratories stock facts
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Primary exchange: Nasdaq
- Prior close Lang & Schwarz (October 5, 2026): EUR 457.75
- Market capitalization: USD 40.7 billion (as of October 6, 2026)
- 52-week range: USD 500.61-769.98 (as of October 6, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies & Distribution
- Index membership: S&P 500
